Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Confidential contracting

- PMLiVE

Marking World Fragile X Day: hundreds of monuments illuminated around the world

Fragile X syndrome is the most common inherited cause of autism and intellectual disabilities worldwide

- PMLiVE

Gilead invests $85m in Gilead Foundation towards health equity progress

The donation follows an endowment announced by the company in 2021 to recapitalise the Foundation

Louise Adamson

Bedrock Healthcare Communications appoints Louise Adamson as Head of Scientific Services

Louise Adamson joins Bedrock as Head of Scientific Services to drive scientific and strategic excellence and grow and develop the scientific team.

Bedrock Healthcare Communications

Navigating the Nuances of Europe’s MedTech Industry

Richard Houlihan, CEO of EirMed, explores topics related to EUDAMED, the European Databank for Medical Devices, including the key pain points and concerns MedTech companies encounter related to EUDAMED and...

Impetus Digital

- PMLiVE

FCB Health Europe appoints two new senior leadership positions

Lucy Morgan is now managing director in the UK and Isabel Rojas is appointed head of planning in Europe

- PMLiVE

Alzheimer’s Research UK welcomes ambitions for dementia set out in first women’s health strategy

The ten-year strategy follows the charity’s calls for action to tackle dementia’s disproportionate impact on women

- PMLiVE

Bristol Myers Squibb launches initiative to ensure disability diversity in clinical trials

Current common clinical trial practices exclude up to a quarter of the US population based on disability status

- PMLiVE

Sandoz’s biosimilar medicine application accepted by FDA

If approved, the higher concentration formulation could decrease the number of injections required for patients currently receiving a lower dose of Hyrimoz

COS and Genesis Research

Genesis Research and Clinical Outcomes Solutions announce innovative partnership

International Real-World Evidence (RWE) and Health Economics and Outcomes Research (HEOR) organization Genesis Research is delighted to announce an exciting new partnership with Clinical Outcomes Assessment (COA) specialist Clinical Outcomes...

Genesis Research Group

- PMLiVE

Almirall launches call on AlmirallShare to find innovative therapies for skin diseases

Since its launch, the R&D platform has received over 560 proposals from over 50 countries

- PMLiVE

Biopharma industry launches Berlin Declaration to ensure equal access during future pandemics

The Declaration outlines a framework that could help to ensure that lower-income countries receive pandemic vaccines and treatments

- PMLiVE

FDA approves Incyte’s Opzelura for vitiligo

It is the first and only FDA-approved product for repigmentation in patients with nonsegmental vitiligo

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links